Merck begins rolling submission for molnupiravir to treat Covid-19 patients in Canada
Merck, called MSD outside the US and Canada, has initiated a rolling submission to Health Canada for molnupiravir, an investigational oral antiviral therapy for the treatment of Covid-19.